WestPark Capital Initiates Coverage On Akebia Therapeutics with Buy Rating, Announces Price Target of $4.5

Benzinga Newsdesk www.benzinga.com Neutral 62.1%

Neg 0% Neu 62.1% Pos 0%

WestPark Capital analyst Ed Arce initiates coverage on Akebia Therapeutics (NASDAQ:AKBA) with a Buy rating and announces Price Target of $4.5.